Notice of Closed Meeting, 66266 [2018-27894]
Download as PDF
<![CDATA[
66266
Federal Register / Vol. 83, No. 246 / Wednesday, December 26, 2018 / Notices
who play on natural grass fields will
provide a comparison group and allow
for evaluation of exposures to
constituents in tire crumb rubber among
synthetic turf field users.
The respondents will be administered
a detailed questionnaire on activity
patterns on synthetic turf with crumb
rubber infill. This instrument will be
used to characterize exposure scenarios,
including the nature and duration of
potential exposures. Additionally, the
questionnaire will include queries on
potential external sources, such as
dietary sources, to select chemicals. We
will collect urine samples pre- and postactivity. The urine samples will be
analyzed for polyaromatic hydrocarbons
and also archived for future analysis in
the event of new analytical methods for
potential chemicals of interest.
The research study will screen a total
of 220 participants for eligibility. The
target sample size for synthetic turf field
users is 150 and 50 for the natural grass
field users. The total burden hours for
the research study is 184 hours among
all of the 220 respondents. There is no
cost to the respondents other than their
time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average
burden per
response
(in hrs.)
Total burden
(in hrs.)
Form name
Adult/Adolescent Field Users ............
Youth/Child
Eligibility Screening Form ................
Adult and Adolescent Questionnaire
Exposure Measurement Form .........
Eligibility Screening Form ................
110
100
100
110
1
1
1
1
5/60
30/60
20/60
5/60
9
50
33
9
Youth/Child Field Users ....................
Youth and Child Questionnaire ........
Exposure Measurement Form .........
100
100
1
1
30/60
20/60
50
33
Total ...........................................
...........................................................
........................
........................
........................
184
Parents/Guardians
Field Users.
of
Jeffrey M. Zirger,
Acting Lead, Information Collection Review
Office, Office of Scientific Integrity, Office
of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2018–27854 Filed 12–21–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
amozie on DSK3GDR082PROD with NOTICES1
Number of
respondents
Type of respondents
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)—DP19–004,
Improving Detection and Management of
VerDate Sep<11>2014
20:07 Dec 21, 2018
Jkt 247001
Glaucoma and Other Eye Diseases Among
High Risk Populations.
Dates: March 26, 2019.
Times: 10:00 a.m.–6:30 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
kva5@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2018–27894 Filed 12–21–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)–PS19–001, The GAIN
(Greater Access and Impact with NAT).
Study: Improving HIV Diagnosis, Linkage
to Care, and Prevention Services with HIV
Point-of-Care Nucleic Acid Tests (NATs).
Date: April 11, 2019.
Time: 10:00 a.m.–5:00 p.m., (EDT).
Place: Teleconference, Centers for Disease
Control and Prevention, Room 1080, 8
Corporate Square Blvd., Atlanta, GA 30329.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Gregory
Anderson, M.S., M.P.H., Scientific Review
Officer, CDC, 1600 Clifton Road, NE,
Mailstop E60, Atlanta, Georgia 30333, (404)
718–8833, gca5@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
E:\FR\FM\26DEN1.SGM
26DEN1
]]>Agencies
[Federal Register Volume 83, Number 246 (Wednesday, December 26, 2018)]
[Notices]
[Page 66266]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27894]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel (SEP)--DP19-004, Improving
Detection and Management of Glaucoma and Other Eye Diseases Among
High Risk Populations.
Dates: March 26, 2019.
Times: 10:00 a.m.-6:30 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488-6511, kva5@cdc.gov.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal
Register notices pertaining to announcements of meetings and other
committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and
Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2018-27894 Filed 12-21-18; 8:45 am]
BILLING CODE 4163-18-P
